Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Giredestrant in ER+/HER2- Early Breast Cancer Intolerant to Aromatase Inhibitors
NCT07541079Phase 3Recruiting
- Sponsor
- Genentech
- Start
- Aug 2026
- Primary completion
- Jun 2032
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of giredestrant in breast cancer, sponsored by Genentech. Started Aug 2026; status: recruiting.
02
Drugs
giredestrant
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT07541079.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07541079.